Subtype
Osteosarcoma
CI-CAN-00001321Explore in graph →
99 active trials6 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001321Explore in graph →
Clinical trials
349 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (40)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04698785 | Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients(REGOMAIN) | recruiting | Phase 2 | 36 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06562673 | Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma(IACE-OS) | completed | Phase 1 / Phase 2 | 10 | Shanghai 6th People's HospitalOTHER | 1 |
| Dec 29, 2025 |
| clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04803877 | SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma | active not recruiting | Phase 2 | 48 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT05182164 | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas(PEMBROCABOSARC) | recruiting | Phase 2 | 119 | Institut BergoniéOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07142863 | Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients | not yet recruiting | Phase 2 | 23 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05588648 | Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | recruiting | Phase 1 / Phase 2 | 48 | MedPacto, Inc.INDUSTRY | 2 | Apr 10, 2025 | clinicaltrials |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT06778603 | B7-H3 NIR Imaging for Osteosarcoma Surgery(ROLN-B7-H3) | recruiting | Phase 1 / Phase 2 | 32 | Peking University People's HospitalOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06650514 | A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma(Osteomyc) | recruiting | Phase 2 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT06714383 | Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma | recruiting | Phase 2 | 50 | Peking University People's HospitalOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05830123 | ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas | recruiting | Phase 2 | 170 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06524778 | Single High-dose Brachytherapy for Giant Osteosarcoma Masses | not yet recruiting | Phase 2 | 16 | Shanghai Jiao Tong University Affiliated Sixth People's HospitalOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT03320330 | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Children's Oncology GroupNETWORK | 1 | Jul 15, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT01459484 | ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma(ISG/OS-2) | completed | Phase 2 | 225 | Italian Sarcoma GroupNETWORK | 1 | May 20, 2024 | clinicaltrials |
| NCT05926492 | A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma | unknown | Phase 2 | 160 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05057130 | Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors | unknown | Phase 2 / Phase 3 | 50 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02470091 | Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 56 | Children's Oncology GroupNETWORK | 3 | Jan 22, 2024 | clinicaltrials |
| NCT06217003 | Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT01336803 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI(Osteosarcoma) | completed | Phase 2 | 32 | Heike E Daldrup-LinkOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04365660 | 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma | terminated | Phase 2 | 1 | Davidzon, Guido, M.D.OTHER | 1 | Nov 14, 2023 | clinicaltrials |
| NCT06125171 | Tucidinostat Plus Apatinib for Advanced Osteosarcoma | unknown | Phase 2 | 46 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT02048371 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | completed | Phase 2 | 131 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06114225 | Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (PROMIS): a Prospective Clinical Trial(PROMIS) | recruiting | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03742193 | Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy(PROACH) | unknown | Phase 2 | 43 | Ruijin HospitalOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT02484443 | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 5 | Oct 26, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT06041490 | Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | not yet recruiting | Phase 2 | 88 | Peking Union Medical College HospitalOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | terminated | Phase 1 / Phase 2 | 12 | Y-mAbs TherapeuticsINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00667342 | A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | completed | Phase 2 | 43 | St. Jude Children's Research HospitalOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04758000 | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse(Metform-Bone) | recruiting | Phase 2 | 67 | Istituto Ortopedico RizzoliOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02432274 | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma | completed | Phase 1 / Phase 2 | 117 | Eisai LimitedINDUSTRY | 6 | Jul 11, 2023 | clinicaltrials |
| NCT03718091 | M6620 (VX-970) in Selected Solid Tumors | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05590572 | A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | not yet recruiting | Phase 1 / Phase 2 | 148 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Oct 21, 2022 | clinicaltrials |
| NCT02357810 | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | completed | Phase 2 | 178 | Northwestern UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02487979 | Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 3 | Jan 18, 2022 | clinicaltrials |
| NCT05116800 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Dec 7, 2021 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT04886765 | A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | unknown | Phase 1 / Phase 2 | 238 | AlaMab Therapeutics (Shanghai) Inc.INDUSTRY | 0 | May 14, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01759303 | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | terminated | Phase 2 | 12 | Emerald Clinical Inc.INDUSTRY | 1 | Apr 13, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2026source: clinicaltrials